Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3028425rdf:typepubmed:Citationlld:pubmed
pubmed-article:3028425lifeskim:mentionsumls-concept:C0021467lld:lifeskim
pubmed-article:3028425lifeskim:mentionsumls-concept:C0023277lld:lifeskim
pubmed-article:3028425lifeskim:mentionsumls-concept:C1704259lld:lifeskim
pubmed-article:3028425lifeskim:mentionsumls-concept:C1156395lld:lifeskim
pubmed-article:3028425lifeskim:mentionsumls-concept:C1158368lld:lifeskim
pubmed-article:3028425lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:3028425lifeskim:mentionsumls-concept:C1705987lld:lifeskim
pubmed-article:3028425lifeskim:mentionsumls-concept:C0030895lld:lifeskim
pubmed-article:3028425lifeskim:mentionsumls-concept:C0591962lld:lifeskim
pubmed-article:3028425pubmed:issue2lld:pubmed
pubmed-article:3028425pubmed:dateCreated1987-3-5lld:pubmed
pubmed-article:3028425pubmed:abstractTextThe biochemical mechanism of action of antimony (Sb) in pentavalent form complexed to gluconic acid (sodium stibogluconate)--the drug of choice for the leishmaniases--has been only slightly investigated. We recently reported that, in stibogluconate-exposed Leishmania mexicana amastigotes, there is a dose-dependent decrease in the ATP/ADP ratio [Berman et al., Antimicrob. Agents Chemother. 27, 916 (1985)]. To investigate mechanisms by which ADP phosphorylation to ATP might be inhibited, stibogluconate-exposed amastigotes were incubated with [14C]glucose, fatty acid, or acetate, and 14CO2 production was determined. In organisms exposed to 500 micrograms Sb/ml, formation of 14CO2 from [6-14C]glucose and [1-14C]palmitate was inhibited 69 and 67% respectively. In comparison, formation of 14CO2 from [1-14C]glucose and [2-14C]acetate was inhibited less than 15%. These results suggest that glucose catabolism via glycolytic enzymes and fatty acid beta-oxidation, but not glucose metabolism via the hexosemonophosphate shunt or the citric acid cycle, is specifically inhibited in stibogluconate-exposed Leishmania mexicana amastigotes. Inhibition of these pathways suggests a mechanism for the inhibition of ADP phosphorylation previously reported.lld:pubmed
pubmed-article:3028425pubmed:languageenglld:pubmed
pubmed-article:3028425pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3028425pubmed:citationSubsetIMlld:pubmed
pubmed-article:3028425pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3028425pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3028425pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3028425pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3028425pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3028425pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3028425pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3028425pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3028425pubmed:statusMEDLINElld:pubmed
pubmed-article:3028425pubmed:monthJanlld:pubmed
pubmed-article:3028425pubmed:issn0006-2952lld:pubmed
pubmed-article:3028425pubmed:authorpubmed-author:BestJ MJMlld:pubmed
pubmed-article:3028425pubmed:authorpubmed-author:BermanJ DJDlld:pubmed
pubmed-article:3028425pubmed:authorpubmed-author:GallaleeJ VJVlld:pubmed
pubmed-article:3028425pubmed:issnTypePrintlld:pubmed
pubmed-article:3028425pubmed:day15lld:pubmed
pubmed-article:3028425pubmed:volume36lld:pubmed
pubmed-article:3028425pubmed:ownerNLMlld:pubmed
pubmed-article:3028425pubmed:authorsCompleteYlld:pubmed
pubmed-article:3028425pubmed:pagination197-201lld:pubmed
pubmed-article:3028425pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:3028425pubmed:meshHeadingpubmed-meshheading:3028425-...lld:pubmed
pubmed-article:3028425pubmed:meshHeadingpubmed-meshheading:3028425-...lld:pubmed
pubmed-article:3028425pubmed:meshHeadingpubmed-meshheading:3028425-...lld:pubmed
pubmed-article:3028425pubmed:meshHeadingpubmed-meshheading:3028425-...lld:pubmed
pubmed-article:3028425pubmed:meshHeadingpubmed-meshheading:3028425-...lld:pubmed
pubmed-article:3028425pubmed:meshHeadingpubmed-meshheading:3028425-...lld:pubmed
pubmed-article:3028425pubmed:meshHeadingpubmed-meshheading:3028425-...lld:pubmed
pubmed-article:3028425pubmed:meshHeadingpubmed-meshheading:3028425-...lld:pubmed
pubmed-article:3028425pubmed:meshHeadingpubmed-meshheading:3028425-...lld:pubmed
pubmed-article:3028425pubmed:meshHeadingpubmed-meshheading:3028425-...lld:pubmed
pubmed-article:3028425pubmed:meshHeadingpubmed-meshheading:3028425-...lld:pubmed
pubmed-article:3028425pubmed:meshHeadingpubmed-meshheading:3028425-...lld:pubmed
pubmed-article:3028425pubmed:meshHeadingpubmed-meshheading:3028425-...lld:pubmed
pubmed-article:3028425pubmed:year1987lld:pubmed
pubmed-article:3028425pubmed:articleTitleSodium stibogluconate (Pentostam) inhibition of glucose catabolism via the glycolytic pathway, and fatty acid beta-oxidation in Leishmania mexicana amastigotes.lld:pubmed
pubmed-article:3028425pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3028425lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3028425lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3028425lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3028425lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3028425lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3028425lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3028425lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3028425lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3028425lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3028425lld:pubmed